The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Akt, and ...

In April 2009, The Lancet Oncology published the findings of a working group (36 scientists from 16 countries) that met in February 2009 at the International Agency for Research on Cancer (Lyon, France) to reassess the carcinogenicity of the biological agents classified as “carcinogenic to humans” (group 1) [1]. With regard to human immunodeficiency virus (HIV) infection, a clear link has been ...

AIMS To evaluate antibodies directed against CD31 (JC70/A) and CD34 (QBEND/10 and anti-HPCA-1) more extensively in Kaposi sarcoma; to assess their value in routine diagnosis; and to compare them with the traditional endothelial cell markers Ulex europaeus agglutinin 1 (UEA-1) and factor VIII related antigen. METHODS Twenty four cases of Kaposi sarcoma were studied retrospectively. All specime...

Abstract: Sexually transmitted diseases (STDs) are through sexual contact, and can manifest in the oral cavity. This study aimed to determine manifestations of STDs. was a literature review using two databases namely Google scholar PubMed. The results obtained six cross-sectional studies. Oral that could occur patients with STD were necrotizing ulcerative gingivitis, periodontitis, stoma-titis,...

Earlier studies have shown that Kaposi sarcomas contain cells infected with human herpesvirus (HHV) 6B, and in current studies we report that both AIDSassociated and classic-sporadic Kaposi sarcoma contain HHV-7 genome sequences detectable by PCR. To determine the distribution of HHV-7-infected cells relative to those infected with HHV-6, sections from paraffin-embedded tissues were allowed to ...

Kaposi's sarcoma (KS) is a highly vascular tumour, which was first described by the Hungarian dermatologist Moritz Kaposi Kohn before the discovery of the human immunodeficiency virus (HIV). Historically, KS has been linked to immunosuppression or to elderly male patients, especially in relation to diffuse cutaneous KS. We describe a case of Bronchopulmonary Kaposi's sarcoma in a patient with A...

Intra-host tumor virus variants may influence the pathogenesis and treatment responses of some virally-associated cancers. However, intra-host variability Kaposi sarcoma-associated herpesvirus (KSHV), etiologic agent sarcoma (KS), has to date been explored with sequencing technologies that possibly introduce more errors than which occurs in viral population, these studies have only studied vari...

Kaposi's sarcoma (KS) is a multicentric vascular neoplasm associated with the Kaposi's sarcoma-associated herpes virus (KSHV). KS can occur in immunocompromised patients as well as certain populations in Africa or in the Mediterranean. Less than 5% of KS cases can present with lymphangioma-like kaposi sarcoma (LLKS), which can occur in all KS variants. KS presents with characteristic skin lesio...

Kaposi sarcoma (KS) is a complex cancer that arises from the initial infection of an appropriate endothelial or progenitor cell by Kaposi Sarcoma Herpesvirus/Human Herpesvirus-8 (KSHV/HHV8). However, the majority of KS cases occur when infected patients also suffer from some coincident form of immune deregulation, providing a favorable microenvironment for tumor development. Cellular hallmarks ...